Patent · US Active

Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF)

US8592563B2 · kind B2 · utility

8Cited by

2References

4Claims

0Family size

Assignees

Philogene, Inc. · US
The University of Bristol · GB

Inventors

David Bates · Bristol, GB
Steven Harper · Roma, IT
Miriam Y. Mengelus · Holon, IL
Menachem Ze'evi · Ramat Gan, IL

Key dates

Filing date	Oct 26, 2008
Grant date	Nov 26, 2013
Priority date	—
Expiry date	Oct 26, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, against agonist pro-angiogenic, pro-permeability, vasodilatory isoforms of VEGF. Disclosed antibodies and antibody fragments are characterized by being capable of binding to and neutralizing pro-angiogenic forms of VEGF while not effecting isoforms of VEGF which are anti angiogenic. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.